

PatientID: HIVDR-815-23

Sebuttemba 27, 2023

Color Code

■ HR: High-Level Resistance ■ PLR: Potential Low-Level Resistance
■ LR: Low-Level Resistance ■ IR: Intermediate Resistance
■ S: Susceptible

| DRUG.CLASS | DRUG | RESISTANCE.PROFILE | DRMS.above.20.percent.prevalence |
|------------|------|--------------------|----------------------------------|
| PI | ATV | IR | M46I;I54L;K20T;L23I |
| | DRV | LR | |
| | FPV | HR | |
| | IDV | LR | |
| | LPV | IR | |
| | NFV | HR | |
| | SQV | IR | |
| | TPV | S | |
| NRTI | ABC | IR | M41L;M184V;T215Y |
| | AZT | HR | |
| | D4T | IR | |
| | DDI | IR | |
| | FTC | HR | |
| | LMV | HR | |
| | TDF | LR | |
| NNRTI | DOR | S | |
| | EFV | S | |
| | ETR | S | |
| | NVP | LR | |
| | RPV | S | |
| INSTI | BIC | S | |
| | CAB | S | |
| | DTG | S | |
| | EVG | PLR | |
| | RAL | PLR | |

Appendix

Drug abbreviations in full

| DRUG.CLASS | ABBREVIATION | DRUG.NAME |
|--------------|--------------|----------------|
| PI | ATV | Atazanavir |
| | DRV | Darunavir |
| | FPV | Fosamprenavir |
| | IDV | Indinavir |
| | LPV | Lopinavir |
| | NFV | Nelfinavir |
| | SQV | Saquinavir |
| | TPV | Tipranavir |
| NRTI | ABC | Abacavir |
| | AZT | Azidothymidine |
| | DFT | Stavudine |
| | DDI | Didanosine |
| | FTC | Emtricitabine |
| | LMV | Lamivudine |
| | TDF | Tenofovir |
| NNRTI | DOR | Doravirine |
| | EFV | Efavirenz |
| | ETR | Etravirine |
| | NVP | Nevirapine |
| | RPV | Rilpivirine |
| INSTI | BIC | Bictegravir |
| | CAB | Cabotegravir |
| | DTG | Dolutegravir |
| | EVG | Elvitegravir |
| | RAL | Raltegravir |

Comments

| DRUG.CLASS | COMMENTS |
|--------------|--|
| PI | I54M/L are non-polymorphic mutations selected primarily by FPV and DRV. I54M/L reduce susceptibility to LPV, ATV, and DRV. |
| | L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It appears to have minimal if any effects on the susceptibility to other PIs. |
| | M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV. |
| | |
| NRTI | M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication. |
| | M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility. |
| | T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF. |
| NNRTI | |

| | |
|--------------|--|
| INSTI | T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to each of the INSTIs. |
|--------------|--|